🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pat LoRusso opening the 2025 AACR Annual Meeting in Chicago

Strong signals on the critical importance of diversity and inclusion in science and maintained public funding of medical research by multiple distinguished speakers during the AACR opening ceremony

Successful FORTRESS meeting series is now resulting in first scientific publications, e.g. a guideline paper on the establishment of patient-derived 3D in vitro models of sarcomas. Congratulations to the very active working group members. Read De Cock L et al. in Neoplasia 2025

This article will likely end up as my favourite translational research paper of the year: Phase behavior of Cacio e Pepe sauce pubs.aip.org/aip/pof/articl…

Invite to FORTRESS translational research workshop (Leuven, Feb. 2026) mailed around earlier this week. Don’t forget to register NOW. By invitation only. Attendance limited to 130 participants and only one guest can win the famous trophy! kuleuven.be/fortress/locat…

A month after closing out an amazing #AACR25 in Chicago, it is great to be back in Chicago with AACR Immediate Past President Pat LoRusso and Margaret Foti, PhD, MD (hc) Marge Foti for #ASCO25.

Interested in Langerhans, Erdheim-Chester, Rosai-Dorfman and other super rare histiocytic neoplasms? Good summary of real-world experience in the Low Countries with targeted treatments in Kemps et al. doi: 10.1016/j.bneo.2024.100023

Sanofi acquired Blueprint Medicines Corporation, the developer of avapritinib, elenestinib and BLU-808. Important nieuws for GIST and systemic mastocytosis experts.

Can hardly recall that I ever had 4 ongoing, actively recruiting, sarcoma-specific first in human Phase 1 trials at the same time. ADCs, bifunctional antibodies and novel kinase inhibitors - what a privilege, really can’t complain… Send your patients for these exclusive trials!

The European Medicines Agency’s Committee for Medicinal Products has recommended granting marketing authorization for nirogacestat for the treatment of adults with progressing desmoid tumors. See also c.peerview.com/live/programs/…

Ripretinib commercially available in Belgium as of today for patients with advanced GIST who received prior treatment with three or more kinase inhibitors including imatinib. It took forever but finally also our patients gain access to the well tolerated and active oral agent

The daily influx of stupid email invitations to commercial, in part predatory scientific meetings is incredible. Today I was invited to a conference “Beauty Meets Science”. Why would someone want to discuss the latest trends in the cosmetology market with an oncologist?

Amorphophallus titanum Becc. (Araceae) with its spectacular 3-8 year flowering life cycle and foul odor resembling rotten flesh when it blooms at Botanical Garden Berlin earlier this week - 230 cm of natural beauty!

Very thankful for 10 years of continued support for our research: The Hans and Els Vandamme Fund for Personalized Cancer Research at KULeuven

Merck KGaA acquired Springworks Therapeutic, the company behind nirogacestat for desmoid fibromatosis, and mirdametinib, the only FDA-approved therapy for NF1-related symptomatic plexiform neurofibromas. Looking forward to trials with drugs from Merck’s rare disease portfolio

Ascleipieon in Kos (Greece) - the birthplace of modern medicine, 200 years bc

The Malouf Lab at IGBMC (Strasbourg, France) is recruiting a postdoctoral researcher to join a translational research program focused on rare and treatment-resistant kidney cancers. 🔗 Full details here: igbmc.fr/en/job-offers/… Let’s build something meaningful IGBMC Students and Post-docs Board (SPB)

CTOS is launching a Young Investigators Group for the next generation of sarcomologists. Get involved!